Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	09/954571	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/02/06 09:50
L2	45	Chien Kenneth	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2006/02/06 09:51
L3	1	(ikeda NEAR yasuhiro) and Kenneth	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/02/06 09:51
L4	236	phospholamban	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/02/06 09:51
L5	56448	gene therapy	US-PGPUB; USPAT; EPO; JPO; DERWENT	ADJ	ON	2006/02/06 09:51
L6	254799	cardiac heart cardio$5	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/02/06 09:51
L7	92	L4 and L5 and L6	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/02/06 09:51
L8	6	L7 and phospholamban.clm.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/02/06 09:52
L9	8	phospholamban mutant	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2006/02/06 09:52
L10	9	(US-20020032167-$ or US-20030050259-$ or US-20030166593-$ or US-20040121942-$ or US-20040191802-$).did. or (US-6174871-$ or US-6416510-$ or US-6716196-$).did. or (WO-200025804-$).did.	US-PGPUB; USPAT; DERWENT	OR	ON	2006/02/06 09:52

```
=> d his

     (FILE 'HOME' ENTERED AT 10:12:07 ON 06 FEB 2006)

     FILE 'MEDLINE, AGRICOLA, CAPLUS, SCISEARCH, BIOSIS' ENTERED AT 10:12:22
     ON 06 FEB 2006
L1         6204 S PHOSPHOLAMBAN
L2       127774 S GENE THERAPY
L3         9701 S L2 AND (HEART OR CARDIAC OR CARDIO?)
L4           92 S L1 (L) L3
L5           63 DUP REM L4 (29 DUPLICATES REMOVED)
L6           21 S L5 AND PY<=2000
L7           21 SORT L6 PY
L8            3 S L7 AND MUT?
L9            0 S L1 AND S16E
               E IKEDA YASUHIRO?/AU
L10         271 S E1
L11          11 S L10 AND L3
L12           9 DUP REM L11 (2 DUPLICATES REMOVED)
L13           9 FOCUS L12 1-

=> d an ti so au ab pi l13 1 3 6 9

L13  ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2004:522697  CAPLUS
DN   141:272021
TI   Development and prospect of gene therapy of
     heart failure
SO   Kemikaru Enjiniyaringu (2004), 49(6), 427-432
     CODEN: KEENAT; ISSN: 0387-1037
AU   Ikeda, Yasuhiro; Yamada, Michio; Matsuzaki, Masunori
AB   A review.  Advantage and disadvantage of general viral and non-viral
     genetic vectors were first discussed.  Gene introduction procedures especially
     developed for cardiac myocyte transfection were then discussed.
     The procedure included steps of lowering body-temperature, temporal
     cardiac arrest, histamine administoration, viral vector
     administoration and heartbeat initiation completed in 5 .apprx. 6 min.
     Potential applications of the procedure to gene
     therapies for dilated cardiomyopathy and chromic
     heart failure were discussed.  Dystrophin-associated
     δ-sarcoglycan gene, BARK (β-adrenergic receptor kinase)
     inhibitor gene and SERCA2a gene were described as candidate transgenes
     that would be introduced in the gene therapies.

L13  ANSWER 3 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2002:185693  CAPLUS
DN   136:242914
TI   High efficiency cardiac gene transfer with adeno-associated
     virus vectors and uses in gene therapy for
     cardiac diseases
SO   U.S. Pat. Appl. Publ., 12 pp.
     CODEN: USXXCO
IN   Chien, Kenneth R.; Hoshijma, Masahiko; Ross, John; Ikeda, Yasuhiro
AB   The present invention discloses methods for the delivery of genes to
     improve cardiac function including the use of adeno-associated
     virus (AAV) vectors, isolation of the heart from systemic
     circulation, and induction of hypothermia/cardiac arrest.  The
     methods result in high-level, long-term expression of reporter genes and
     enhanced cardiac function in hamster models of heart
     disease.  In particular, the gene expression via AAV vectors is highly
     restricted to cardiac muscle and maintained long-term, with no
     sign of myocardial inflammation.  Transfer of a gene for a dominant neg.
     form of phospholamban enhanced the contractility in the heart of
     hamsters, suppressing heart failure by enhancing the function of
     sarcoplasmic reticulum calcium ATPase 2.
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    --------------------   --------
PI   US 2002032167        A1    20020314    US 2001-954571         20010911
     CA 2422078           AA    20020321    CA 2001-2422078        20010911
```

WO 2002022177 A2 20020321 WO 2001-US29103 20010911
WO 2002022177 A3 20021128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2001091063 A5 20020326 AU 2001-91063 20010911
EP 1317289 A2 20030611 EP 2001-971139 20010911
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

L13 ANSWER 6 OF 9 MEDLINE on STN
AN 2002402556 MEDLINE
TI Chronic suppression of **heart**-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo **cardiac** rAAV gene delivery.
SO Nature medicine, (2002 Aug) 8 (8) 864-71. Electronic Publication: 2002-07-22.
Journal code: 9502015. ISSN: 1078-8956.
AU Hoshijima Masahiko; **Ikeda Yasuhiro**; Iwanaga Yoshitaka; Minamisawa Susumu; Date Moto-o; Gu Yusu; Iwatate Mitsuo; Li Manxiang; Wang Lili; Wilson James M; Wang Yibin; Ross John Jr; Chien Kenneth R
AB The feasibility of **gene therapy** for **cardiomyopathy**, **heart** failure and other chronic **cardiac** muscle diseases is so far unproven. Here, we developed an in vivo recombinant adeno-associated virus (rAAV) transcoronary delivery system that allows stable, high efficiency and relatively **cardiac** -selective gene expression. We used rAAV to express a pseudophosphorylated mutant of human phospholamban (PLN), a key regulator of **cardiac** sarcoplasmic reticulum (SR) Ca(2+) cycling in BIO14.6 **cardiomyopathic** hamsters. The rAAV/S16EPLN treatment enhanced myocardial SR Ca(2+) uptake and suppressed progressive impairment of left ventricular (LV) systolic function and contractility for 28-30 weeks, thereby protecting **cardiac** myocytes from cytopathic plasma-membrane disruption. Low LV systolic pressure and deterioration in LV relaxation were also largely prevented by rAAV/S16EPLN treatment. Thus, transcoronary gene transfer of S16EPLN via rAAV vector is a potential therapy for progressive dilated **cardiomyopathy** and associated **heart** failure.

L13 ANSWER 9 OF 9 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
AN 2000:303888 BIOSIS
TI In vivo **cardiac** gene transfer in hamsters using hypothermic **cardiac** arrest.
SO FASEB Journal, (March 15, 2000) Vol. 14, No. 4, pp. A420. print.
Meeting Info.: Annual Meeting of Professional Research Scientists: Experimental Biology 2000. San Diego, California, USA. April 15-18, 2000. Federation of American Societies for Experimental Biology.
CODEN: FAJOEC. ISSN: 0892-6638.
AU **Ikeda, Yasuhiro**; Gu, Yusu; Oh, Sam; Giordano, Frank J.; Hoshijima, Masahiko; Chen, Ju; Peterson, Kirk L.; Ross, John, Jr.